Nootropics Powder 99% Purity Vinpocetine powder CAS: 42971-09-5
Common Name(s): Vinpocetine , Cavinton , apovincaminic acid kavinton
The scientific literature contains numerous studies and
investigations on the pharmacological and biochemical actions of
vinpocetine, including antioxidant effects, menopause, antiulcer
activity, and phosphodiesterase-1 inhibition. Vinpocetine is best
known for its neuroprotective effects. However, there are limited
clinical studies to support the use of vinpocetine for many of
these potential uses.
Follow suggested manufacturers' product guidelines. Most clinical
studies used vinpocetine 10 mg 3 times daily, orally or
The drug should not be used in patients with severe, general,
cerebral hypertensive crises, or in elderly or senile patients with
acute cardio-cerebral or cerebro-cardiac syndrome, postinfarction
cardiosclerosis, or marked disorders of heart rhythm.
Avoid use during pregnancy and lactation because of lack of
Caution is warranted in patients on blood-thinning medications
because vinpocetine decreases platelet aggregation. In 1 study,
bioavailability increased 60% to 100% when vinpocetine was taken
One review article documents patients reporting flushing, rashes,
and minor GI problems.
Mechanism of action
Vinpocetine has been shown to selectively inhibit voltage-sensitive
Na+ channels, resulting in a dose-dependent decrease in evoked
extracellular Ca++ ions in striatal nerve endings. The Na+ channel
inhibiting properties of vinpocetine are thought to contribute to a
general neuroprotective effect through blockade of excitotoxicity
and attenuation of neuronal damage induced by cerebral
Vinpocetine is also a phosphodiesterase (PDE) type-1 inhibitor,
(with an IC50 of approximately 10−5 M.) leading to increases in
intracellular levels of cyclic guanosine 3'5'-monophosphate (cGMP),
an action that causes the vasorelaxant effects of vinpocetine on
cerebral smooth muscle tissue.
Independent of vinpocetine's action on PDE, vinpocetine inhibits
IKK preventing IκB degradation and the following translocation of
NF-κB to the cell nucleus.
Increases in neuronal levels of DOPAC, a metabolic breakdown
product of dopamine, have been shown to occur in striatal isolated
nerve endings as a result of exposure to vinpocetine. Such an
effect is consistent with the biogenic pharmacology of reserpine, a
structural relative of vinpocetine.However, this effect tends to be
reversible upon cessation of vinpocetine administration, with full
remission typically occurring within 3–4 weeks.